Aurora kinase A (AURKA) expression is a prognostic marker in patients with colorectal cancer

7^th International Conference and Expo on Molecular & Cancer Biomarkers

September 15-16, 2016 Berlin, Germany

Hyun Min Koh

Jeju National University Hospital, Korea(south)

Posters & Accepted Abstracts: J Mol Biomark Diagn

Abstract :

Background & Aim: Aurora kinase A (AURKA), also known as STK15/BTAK, is a member of a serine/threonine kinase family that plays important role in mitosis and maintenance of chromosomal stability. This study evaluates the clinical significance of AURKA expression in colorectal cancer. Methods: Expression of AURKA protein was evaluated by immunohistochemistry in 151 patients with colorectal adenocarcinoma using tissue microarray blocks. We then analyzed relationship between clinicopathological characteristics and AURKA expression. Also we assessed the prognostic significance of various clinicopathological data on progression-free survival(PFS). Results: AURKA expression was detected in 45% (68/151). The positive staining of AURKA was more often detected in the colorectal adenocarcinoma with male patients (P=0.035) and distally located tumor (P=0.021). Progression-free survival of the patients with AURKA positive was shorter than those with AURKA negative (P 0.001). Univariated analysis demonstrated that AURKA expression (P=0.001), age (p=0.034), lymphatic invasion (P=0.001), perineural invasion (P=0.002) and TNM stage (p=0.013) were variables affecting PFS. In a multivariated analysis for PFS, a Cox proportional hazard model confirmed that AURKA expression was an independent and significant prognostic factor in colorectal adenocarcinoma (hazard ratio, 3.944; P 0.001). Conclusions: AURKA could serve as an independent factor to predict a poor prognosis in colorectal cancer.

Biography :

Email: hyunminkoh@hotmail.com